
Explore our recent stories to see what drives us
Grünenthal acquires US-based Valinor Pharma

Movantik® is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing U.S. business. Gross sales from Movantik® in the United States reached over $200 million in 2023.
Fact-Sheet Valinor Pharma & Movantik®
PR Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®
Further details on our company can be found in our annual report.

“As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio.”
Get in touch
We are keen to hear new ideas and discover assets that are relevant to our business. If you are interested in partnering with us, get in touch.
Contact us